Pharmaceuticals News and Research

RSS

Biosolveit, CCDC unveil 3D-based computational drug design

BioSolveIT GmbH in conjunction with The Cambridge Crystallographic Data Centre today announced the release of an exclusive set of fragments for 3D-based computational drug design. The Cambridge Structural Database is a key global source for crystal structures and a major resource for the chemical and pharmaceutical industries. It provides the basis for the highest quality input fragment data for successful fragment-based lead discovery (FBLD) with LeadIT.

25 Mar 2010

ScinoPharm announces record results for fiscal year 2009

ScinoPharm, an active pharmaceutical ingredient specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008.

25 Mar 2010

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

In an address to the American Chamber of Commerce in Germany today, John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, said that innovation holds the key to solving one of healthcare's thorniest dilemmas: how to improve quality and access while controlling costs.

25 Mar 2010

Public and private sectors fund bioprocessing research for drug development

The search for new medicines will receive a £10M boost this week as the public and private sectors unite to fund bioprocessing research. The money is now available for scientists to apply for from the Bioprocessing Research Industry Club (BRIC) which aims to bring academics and industry together to find ways of delivering new medicines from biological materials more quickly and effectively.

25 Mar 2010

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a "10-year deal … to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations," Reuters reports.

25 Mar 2010

New ultrasound device shows promising results for treating joint and muscle pain

It's lightweight, smaller than most iPods and can deliver low-intensity ultrasound therapy for up to 10 hours. It just might revolutionize pain relief - and save patients time.

25 Mar 2010

Payers can improve risk-sharing approaches for expensive therapies and technology

Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that it has published the collective recommendations of an international team of healthcare experts on how payers can improve their risk-sharing approaches for expensive new therapies and technology.

25 Mar 2010

Majority of Americans blame insurers and drug makers for rising health-care costs

Forty-four percent of U.S. adults are "extremely worried" or "very worried" about paying for rising health-care costs. And the top reasons cited for those rising costs are profits generated by drug companies and health insurance companies.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

China set to dominate prescription drug markets

New reports indicate that prescription drug sales in emerging markets will grow quickly, especially in the hugely influential market of China. In fact, China's pharmaceutical market continues to expand its dominance and clout at an astonishing rate.

25 Mar 2010

New series of filters screen compounds for drug development

The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute's medicinal chemistry group.

25 Mar 2010

Xifaxan drug receives FDA approval

The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.

25 Mar 2010

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

PPD, Inc. (Nasdaq: PPDI) today announced it is launching the PPD Vaccines & Biologics Center of Excellence, a first-in-kind comprehensive network of integrated, world-class laboratory services focused specifically on vaccine and biologic drug development.

24 Mar 2010

InvestorSoup.com announces investment report featuring Oncothyreon

InvestorSoup.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

24 Mar 2010

Transcept Pharmaceuticals receives second patent for Intermezzo formulation

Transcept Pharmaceuticals, Inc. today announced that the second patent covering the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office.

24 Mar 2010

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis. Thirty-two percent of surveyed dermatologists selected Humira as the most efficacious, followed by Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade. The current sales leader Amgen/Pfizer/Takeda's Enbrel was selected as the most efficacious therapy by only 23 percent of dermatologists surveyed.

24 Mar 2010

Policymakers should determine risk-reduction initiatives to improve health systems, says new report

Tackling the increasing rates of cardiovascular disease in developing nations will require input from multiple partners, including the business community and international companies as well as global health and development agencies and the governments of these countries, says a new report from the Institute of Medicine.

24 Mar 2010

Pharmaceuticals News and Research

Biosolveit, CCDC unveil 3D-based computational drug design

ScinoPharm announces record results for fiscal year 2009

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

Public and private sectors fund bioprocessing research for drug development

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

New ultrasound device shows promising results for treating joint and muscle pain

Payers can improve risk-sharing approaches for expensive therapies and technology

Majority of Americans blame insurers and drug makers for rising health-care costs

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Evotec AG reports financial results and corporate updates for 2009

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

China set to dominate prescription drug markets

New series of filters screen compounds for drug development

Xifaxan drug receives FDA approval

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

InvestorSoup.com announces investment report featuring Oncothyreon

Transcept Pharmaceuticals receives second patent for Intermezzo formulation

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Policymakers should determine risk-reduction initiatives to improve health systems, says new report

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence